Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

The Association Between Plasma DPP4 Activity And Prognosis of Patients With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03046576

Enrollment

625

Registered

2017-02-08

Start date

2013-01-01

Completion date

2015-09-30

Last updated

2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Angiography, Dipeptidyl Peptidase 4

Brief summary

Increased plasma DPP4 activity (DPP4a) could predict both subclinical and new-onset atherosclerosis, and our previous study has found that the DPP4a was significantly lower in MI patients compared with patients having chest pain or unstable angina alone, and DPP4a is associated with no-reflow and major bleeding events in STEMI patients during hospital stay. As no-reflow phenomenon and major bleeding events independently associates with a worse in-hospital and long-term prognosis. One may speculate that the DPP4a is associated with long-term follow-up adverse cardiovascular events in these patients.The hypothesis was tested in this study.

Interventions

DIAGNOSTIC_TESTplasma DPP4 activity

DPP4a was determined by enzymatic assays.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* consecutive patients of acute STEMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion criteria

* patients with cancer, and patients who were taking a DPP4 inhibitoror a glucagon-like peptide-1 (GLP-1) analogue

Design outcomes

Primary

Measure	Time frame	Description
major adverse cardiac or cerebrovascular events	The median follow-up was 30 months	including cardiovascular death, non-fatal myocardial infarction, heart failure and stroke

Secondary

Measure	Time frame	Description
non-cardiovascular death	The median follow-up was 30 months	—
repeated revascularization	The median follow-up was 30 months	defined as repeated PCI or bypass grafting of not only infarct related artery but also non-infarct related artery, driven by ischemic symptoms (stable/unstable angina or re-infarction) or detection of ischemia by non-invasive tests
stroke	The median follow-up was 30 months	defined using the World Health Organization criteria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026